Stock Evaluator: ADARx Pharmaceuticals, Inc. (ADRX)

ADARx Pharmaceuticals, Inc. ADRX

$12.79 -1.37 -9.68%
November 20, 2026 4:00:00 PM EST November 10, 2021 Volume: 708,823
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation. It also offers extrahepatic-targeted programs, such as ADX-077, an adipose-targeted obesity program designed to reduce body weight and fat while preserving lean mass; and ADX-199, a neuron-targeted program designed to selectively silence and degrade amyloid-ß precursor protein (APP) mRNA in neurons, which is genetically linked to Alzheimer’s disease. The company was incorporated in 2019 and is based in San Diego, California.

Commentary & Analysis


Financial Summary

Share Statistics ADRX Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $1,412.2 $203.5 51%
Shares Out (Mil) 16.1 55.2 27%
Institutional Ownership 81.1% 93.3% 49%
Float (Mil) 40.0 40.4 41%
Beta na 1.05 na
Avg Daily Volume (000s) 602 569 61%
Price Change
(52-week)
na 38.8% na
Growth ADRX Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.6% na
Net Income (5yr) na (10.7%) na
EPS (5yr) na 15.4% na
Dividends (5yr) na 0.0% 0%
Cash Flow (5yr) na (15.7%) na
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 3 3 3
Current EPS ($0.392) ($2.030) ($1.540)
Month Ago EPS ($0.379) ($1.679) ($1.513)
# Rev Up na na na
# Rev Down na na na
Three Months Ago EPS na na na
Year/Year Chg (77.5%) (73.1%) (76.9%)
Financials ADRX Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $7 $40 7%
Net Income (TTM) (Mil) ($98) ($44) 11%
EPS (TTM) ($8.641) ($1.400) 5%
Operating Cash Flow (TTM) (Mil) ($90) ($35) 7%
Net Cash Flow (TTM) (Mil) $498 $-0 91%
Long-Term Debt (Q1) (Mil) $5 $4 24%
Enterprise Value (Q1) (Mil) $531 $142 35%
Valuation ADRX Industry
Median
Percentile
(All Stocks)
P/B 2.37 1.96 64%
P/E na 16.9 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 0.9 na
Ratios ADRX Industry
Median
Percentile
(All Stocks)
Gross Margin na 67.6% na
Net Margin na (50.8%) na
ROA (21.1%) (47.0%) 19%
ROE (34.2%) (51.8%) 19%
Liabilities to Assets 38.2% 29.6% 29%
F-Score 1 3 na

ADARx Pharmaceuticals, Inc. did not pass any screens on 11/20/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors